Founded in 2014 Bugworks is a drug research and discovery company.

Basic Information

Headquartered in USA with subsidiaries in India and Australia, Bugworks Bugworks Research Inc.is developing a novel class of antibiotics to tackle the problem of Antimicrobial Resistance (AMR). They combine functional proteomics with sophisticated semiconductor design principles to model and to manipulate various bacterial systems. Their model of E. coli is modular and adaptable to tackle a spectrum of pathogens that affects large communities, hospitals and ICUs. Their Microbial Platform (BMP) is also capable of modelling the behaviour and effect of biofilm formation. This in turn permits the evaluation of both phenotypic and genotypic resistance mechanisms, allowing for the design of targeted therapies. Their mission is to use their scientific prowess and business model to innovate, inspire, and implement solutions to combat AMR. See more

Legal Name

:

BUGWORKS Research Inc.

Headquarters

:

Saratoga, California, United States

Founding Date

:

2014

No. of Employees

:

21 to 40

Core Team

:
1.

Anand Anandkumar

Co-founder & CEO

2.

V. Balasubramanian

Co-founder & COO

3.

Santanu Datta

Co-founder & CSO

Funding

Total Funding

$19.0M

Investors

:

1.

3one4 Capital

2.

UTEC- University of Tokyo Edge Capital

3.

Global Brain Corporation

See More

Detail Round Breakdown

Round 1

$18M

Series Name

:

SERIES-B

Date

:

9th Feb 2022

Investors

:
1.

Global Brain Corporation

2.

Acquipharma

3.

UTEC- University of Tokyo Edge Capital

See More